Chest
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only ArticlesAntithrombotic Therapy in Peripheral Artery Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Section snippets
Summary of Recommendations
Note on Shaded Text: Throughout this guideline, shading is used within the summary of recommendations sections to indicate recommendations that are newly added or have been changed since the publication of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Recommendations that remain unchanged are not shaded.
2.1. For persons with asymptomatic peripheral arterial disease (PAD), we suggest aspirin 75 to 100 mg
Estimation of Baseline Risks and Absolute Effects of Treatment
In order to estimate absolute benefits and harms associated with a given therapy, we performed the following steps. First, we generated relative effect estimates (relative risks) from the highest-quality published meta-analysis of randomized controlled trials (RCTs). If no such meta-analyses were available or were out of date, we conducted our own meta-analyses of relevant RCTs or used relative risk estimates from single RCTs in the absence of other relevant RCTs.
Ideally, in order to
Primary Prevention of Cardiovascular Events in Patients With Asymptomatic PAD
As in the article by Vandvik et al4 of this supplement, primary prevention refers to the use of an intervention to prevent events prior to any clinically manifested disease. Hence, even though nearly every 70-year-old man or woman has significant vascular changes, they are candidates for primary (as opposed to secondary) prevention unless they have clinically manifested vascular disease (ie, claudication; history of peripheral vascular procedures; known history of CAD, MI, or stroke).
Most
Antiplatelet Therapies for Secondary Prevention of Cardiovascular Events in Patients With Symptomatic PAD
Because antiplatelet therapy would be expected to result in similar relative reductions in vascular events such as MI or stroke in patients with PAD or CAD, we considered RCTs enrolling patients with PAD, CAD, or both to support our recommendations for both conditions. Although many of the included studies conducted post hoc analyses limited to patients enrolled for symptomatic PAD, we did not find these subgroup analyses credible based on criteria proposed by Sun et al.14 Therefore, our
Antithrombotic Therapy for the Management of Patients With Claudication
In the previous section, we recommended aspirin or clopidogrel for the prevention of nonfatal MI, nonfatal stroke, or vascular death for all patients with symptomatic PAD. In this section, we evaluate other therapies with antiplatelet and antithrombotic properties (eg, cilostazol, pentoxifylline, prostanoids) for their effect on quality of life. Unfortunately, most studies have not evaluated quality of life as an outcome directly and often used walking distance as a surrogate. We make
Critical Limb Ischemia
Patients with critical limb ischemia have inadequate resting blood flow to the lower limbs, resulting in rest pain, ulceration, and eventually gangrene and limb loss. Such patients are candidates for prompt revascularization. Pertinent outcomes include relief of pain, quality of life, and limb salvage.
Acute Limb Ischemia
Acute limb ischemia results from a sudden interruption of blood flow to an extremity.45 The most common causes of nontraumatic acute arterial occlusion are embolism and thrombosis.45, 46, 47 Approximately 80% of peripheral emboli originate in the heart (eg, left atrial appendage, left ventricular apex, native and prosthetic cardiac valves). In the remaining cases, emboli originate from the aorta or peripheral vessels themselves or are of venous origin (paradoxical with migration through patent
Endovascular Revascularization in Patients With Symptomatic PAD
Patients with refractory claudication, rest pain, and ischemia often require revascularization for symptomatic relief and limb salvage. Increasingly, patients are undergoing PTA with or without stent placement. Few studies guide clinicians regarding type and duration of antithrombotic therapy following such procedures. Current practice is very heterogeneous and often is based on indirect evidence from studies in patients undergoing coronary stenting.
Antithrombotic Therapy Following Peripheral Artery Bypass Graft Surgery
In this section, we review evidence from studies evaluating antithrombotic therapy following peripheral bypass surgery. For the most part, these data do not suggest that recommendations for antithrombotic therapy following peripheral artery bypass surgery should differ from that in other patients with symptomatic PAD. One exception is the use of dual antiplatelet therapy in patients following prosthetic graft bypass surgery.
Carotid Artery Stenosis
Carotid stenosis may coexist in asymptomatic patients as well as in symptomatic patients with CAD or PAD. Recent prevalence estimates range from 0.2% in men aged < 50 years to 7.5% in men aged ≥ 80 years.76
Acknowledgments
Author contributions: As Topic Editor, Dr Alonso-Coello oversaw the development of this article, including the data analysis and subsequent development of the recommendations contained herein.
Dr Alonso-Coello: contributed as Topic Editor.
Dr Bellmunt: contributed as a frontline clinician.
Dr McGorrian: contributed as a panelist.
Dr Anand: contributed as a panelist.
Dr Guzman: contributed as a panelist.
Dr Criqui: contributed as a panelist.
Dr Akl: contributed as a panelist.
Dr Vandvik: contributed as
References (86)
- et al.
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
Lancet
(2010) - et al.
Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis
Lancet
(1993) - et al.
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
Lancet
(2011) - et al.
Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study
J Vasc Surg
(2002) - et al.
Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure
J Vasc Surg
(1998) From effect size into number needed to treat
Lancet
(1999)- et al.
The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease
J Vasc Surg
(2009) - et al.
A comparison of cilostazol and pentoxifylline for treating intermittent claudication
Am J Med
(2000) - et al.
Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication
Am J Med
(1999)
Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies
Eur J Vasc Endovasc Surg
Acute limb ischemia
Tech Vasc Interv Radiol
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
J Vasc Surg
Proper evaluation and management of acute embolic versus thrombotic limb ischemia
Semin Vasc Surg
Surgical treatment versus thrombolysis in acute arterial occlusion: a randomised controlled study
Eur J Vasc Surg
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia
J Vasc Surg
Thrombolysis or peripheral arterial surgery: phase I results
J Vasc Surg
Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity
J Vasc Surg
Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions
Eur J Radiol
Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial
J Vasc Surg
Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators
Lancet
Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study
BMJ
Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study
Arterioscler Thromb Vasc Biol
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study
Circulation
Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study
Circulation
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis
JAMA
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
Lancet
Effect of aspirin mortality in primary prevention of cardiovascular disease
Am J Med
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses
BMJ
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events
Lancet
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients
Cochrane Database Syst Rev
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease
Cochrane Database Syst Rev
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
N Engl J Med
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease
N Engl J Med
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis
Arch Intern Med
Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality
Acta Med Scand
Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis
JAMA
Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability
Research Synthesis Methods
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials
EuroIntervention
Cited by (0)
Funding/Support: The Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines received support from the National Heart, Lung, and Blood Institute [R13 HL104758] and Bayer Schering Pharma AG. Support in the form of educational grants were also provided by Bristol-Myers Squibb; Pfizer, Inc; Canyon Pharmaceuticals; and sanofi-aventis US.
Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://chestjournal.chestpubs.org/content/141/2_suppl/1S.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).